SunRock Biopharma, Escugen Partner to Develop CCR9-Targeted ADC
17 Jun 2025 //
BUSINESSWIRE
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
19 Dec 2023 //
PR NEWSWIRE
Shanghai Escugen releases positive results from a first-in-human study of ESG401
05 Jun 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support